Medtronic (NYSE:MDT) EVP Harry Skip Kiil Sells 1,483 Shares

Medtronic PLC (NYSE:MDT) EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Medtronic Trading Up 0.3%

Shares of MDT opened at $92.87 on Friday. The business’s 50-day moving average price is $88.75 and its 200-day moving average price is $84.98. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The stock has a market cap of $118.80 billion, a PE ratio of 22.87, a P/E/G ratio of 2.11 and a beta of 0.56. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s revenue was up 13.7% compared to the same quarter last year. During the same period last year, the business earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.97 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is presently 70.94%.

Wall Street Analyst Weigh In

MDT has been the topic of a number of recent analyst reports. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research report on Monday, August 10th. TD Cowen boosted their target price on Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, August 28th. BTIG Research lifted their price target on Medtronic from $91.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, September 1st. Bank of America boosted their price objective on Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Finally, Mizuho set a $115.00 price objective on shares of Medtronic in a research report on Wednesday, September 2nd. Nineteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $103.92.

Institutional Investors Weigh In On Medtronic

Large investors have recently added to or reduced their stakes in the company. Monetary Solutions Ltd bought a new position in shares of Medtronic during the 4th quarter valued at about $27,000. Basepoint Wealth LLC bought a new stake in Medtronic in the 4th quarter worth approximately $32,000. Tucker Asset Management LLC bought a new stake in Medtronic in the 4th quarter worth approximately $33,000. Modus Advisors LLC purchased a new stake in Medtronic in the fourth quarter worth approximately $36,000. Finally, IAG Wealth Partners LLC purchased a new stake in Medtronic in the second quarter worth approximately $30,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic raised its outlook again as demand for cardiovascular and heart devices continues to climb. Analysts also highlighted market-share gains in electrophysiology and improving momentum across several key franchises, supporting expectations for sustained revenue growth. Medtronic Raises its Outlook Again as Heart Device Demand Keeps Climbing BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
• Positive Sentiment: The FDA cleared Medtronic’s LigaSure RAS Maryland instrument for use with the Hugo robotic-assisted surgery system in the United States. The approval broadens Hugo’s instrument offering and could help Medtronic win additional robotic-surgery procedures and expand the platform’s long-term revenue base. Medtronic Announces FDA Clearance for LigaSure RAS Maryland Instrument
• Positive Sentiment: Coverage of Hugo’s expanding applications presents the surgical-robotics platform as a potential growth engine. Broader clinical use and a larger instrument ecosystem could diversify Medtronic beyond its established device franchises. Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?
• Positive Sentiment: Medtronic’s latest earnings commentary pointed to broad-based growth momentum, complementing its previously reported earnings and revenue beats and year-over-year revenue growth. Medtronic Earnings Call Signals Broad-Based Growth Momentum
• Neutral Sentiment: Medtronic launched a share-exchange offer covering up to approximately 225.4 million newly issued shares as part of its planned diabetes-business spin-off. The transaction may sharpen the company’s strategic focus, although investors will monitor dilution, execution and the final ownership structure. Medtronic Advances Diabetes Spin-Off with Share Exchange
• Neutral Sentiment: Medtronic appointed former ReCor Medical CEO Lara Barghout to lead its Interventional Cardiology Therapies business, adding specialized experience in renal denervation and cardiovascular technology. Recor Medical Former CEO Joins Medtronic
• Negative Sentiment: Executive Vice President Harry Kiil sold 1,483 shares, worth about $139,000. The sale was relatively small and he retained a substantial position, limiting its significance, but insider selling can weigh modestly on sentiment.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.